beta-lapachone has been researched along with Breast Cancer in 18 studies
beta-lapachone: antineoplastic inhibitor of reverse transcriptase, DNA topoisomerase, and DNA polymerase
beta-lapachone : A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We compared the cytotoxic responses of MCF-7:WS8 (MCF-7) human breast cancer cells after 4-h pulses of beta-lap or camptothecin (CPT), a known Topo I poison." | 7.70 | Induction of apoptosis in MCF-7:WS8 breast cancer cells by beta-lapachone. ( Boothman, DA; Bornmann, WG; Byers, KL; Pink, JJ; Planchon, SM; Wuerzberger, SM, 1998) |
| "Phenformin is a mitochondrial complex I inhibitor that induces bioenergetic stress." | 5.62 | STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer. ( Aguilar-Mahecha, A; Ahn, R; Avizonis, D; Basik, M; Cepeda Cañedo, E; Chabot, C; Dankner, M; Goulet, ML; Hébert, S; Im, YK; Kleinman, CL; Kuasne, H; La Selva, R; Lebeau, B; Lewis, K; Lin, R; Martínez, C; Najyb, O; Nguyen, A; Park, M; Petrecca, K; Pollak, M; Sabourin, V; Santos Martínez, N; Savage, P; Siegel, PM; St-Pierre, J; Topisirovic, I; Totten, SP; Ursini-Siegel, J; Witcher, M, 2021) |
| " We compared the cytotoxic responses of MCF-7:WS8 (MCF-7) human breast cancer cells after 4-h pulses of beta-lap or camptothecin (CPT), a known Topo I poison." | 3.70 | Induction of apoptosis in MCF-7:WS8 breast cancer cells by beta-lapachone. ( Boothman, DA; Bornmann, WG; Byers, KL; Pink, JJ; Planchon, SM; Wuerzberger, SM, 1998) |
| "Phenformin is a mitochondrial complex I inhibitor that induces bioenergetic stress." | 1.62 | STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer. ( Aguilar-Mahecha, A; Ahn, R; Avizonis, D; Basik, M; Cepeda Cañedo, E; Chabot, C; Dankner, M; Goulet, ML; Hébert, S; Im, YK; Kleinman, CL; Kuasne, H; La Selva, R; Lebeau, B; Lewis, K; Lin, R; Martínez, C; Najyb, O; Nguyen, A; Park, M; Petrecca, K; Pollak, M; Sabourin, V; Santos Martínez, N; Savage, P; Siegel, PM; St-Pierre, J; Topisirovic, I; Totten, SP; Ursini-Siegel, J; Witcher, M, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 4 (22.22) | 29.6817 |
| 2010's | 9 (50.00) | 24.3611 |
| 2020's | 3 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, SY | 1 |
| Syu, JP | 1 |
| Lo, YT | 1 |
| Chau, YP | 2 |
| Don, MJ | 1 |
| Shy, HT | 1 |
| Lai, SM | 1 |
| Kung, HN | 1 |
| Totten, SP | 1 |
| Im, YK | 1 |
| Cepeda Cañedo, E | 1 |
| Najyb, O | 1 |
| Nguyen, A | 1 |
| Hébert, S | 1 |
| Ahn, R | 1 |
| Lewis, K | 1 |
| Lebeau, B | 1 |
| La Selva, R | 1 |
| Sabourin, V | 1 |
| Martínez, C | 1 |
| Savage, P | 1 |
| Kuasne, H | 1 |
| Avizonis, D | 1 |
| Santos Martínez, N | 1 |
| Chabot, C | 1 |
| Aguilar-Mahecha, A | 1 |
| Goulet, ML | 1 |
| Dankner, M | 1 |
| Witcher, M | 1 |
| Petrecca, K | 1 |
| Basik, M | 1 |
| Pollak, M | 1 |
| Topisirovic, I | 1 |
| Lin, R | 1 |
| Siegel, PM | 1 |
| Kleinman, CL | 1 |
| Park, M | 1 |
| St-Pierre, J | 1 |
| Ursini-Siegel, J | 1 |
| Franca, L | 1 |
| Ferraz, M | 1 |
| Barros, MC | 1 |
| Gibson, V | 1 |
| Xavier-Júnior, FH | 1 |
| Magalhães, NSS | 1 |
| Lira-Nogueira, M | 1 |
| Yang, Y | 1 |
| Zhou, X | 1 |
| Xu, M | 1 |
| Piao, J | 1 |
| Zhang, Y | 1 |
| Lin, Z | 1 |
| Chen, L | 1 |
| Li, X | 1 |
| Jia, X | 1 |
| Niu, H | 1 |
| Kim, DW | 1 |
| Cho, JY | 1 |
| Zada, S | 1 |
| Hwang, JS | 1 |
| Ahmed, M | 1 |
| Lai, TH | 1 |
| Pham, TM | 1 |
| Kim, DH | 1 |
| Kim, DR | 1 |
| Lamberti, MJ | 1 |
| Vittar, NB | 1 |
| da Silva, Fde C | 1 |
| Ferreira, VF | 1 |
| Rivarola, VA | 1 |
| Bey, EA | 1 |
| Reinicke, KE | 1 |
| Srougi, MC | 1 |
| Varnes, M | 1 |
| Anderson, VE | 1 |
| Pink, JJ | 5 |
| Li, LS | 1 |
| Patel, M | 1 |
| Cao, L | 1 |
| Moore, Z | 1 |
| Rommel, A | 1 |
| Boatman, M | 1 |
| Lewis, C | 1 |
| Euhus, DM | 1 |
| Bornmann, WG | 2 |
| Buchsbaum, DJ | 1 |
| Spitz, DR | 1 |
| Gao, J | 1 |
| Boothman, DA | 6 |
| Paludo, CR | 1 |
| da Silva-Junior, EA | 1 |
| de Oliveira Silva, E | 1 |
| Vessecchi, R | 1 |
| Peporine Lopes, N | 1 |
| Tallarico Pupo, M | 1 |
| da Silva Emery, F | 1 |
| Dos Santos Gonçalves, N | 1 |
| Alves Dos Santos, R | 1 |
| Jacometti Cardoso Furtado, NA | 1 |
| Park, MT | 1 |
| Song, MJ | 1 |
| Lee, H | 1 |
| Oh, ET | 1 |
| Choi, BH | 1 |
| Jeong, SY | 1 |
| Choi, EK | 1 |
| Park, HJ | 1 |
| Seoane, S | 1 |
| Díaz-Rodríguez, P | 1 |
| Sendon-Lago, J | 1 |
| Gallego, R | 1 |
| Pérez-Fernández, R | 1 |
| Landin, M | 1 |
| Lin, MT | 1 |
| Chang, CC | 1 |
| Chen, ST | 1 |
| Chang, HL | 1 |
| Su, JL | 1 |
| Kuo, ML | 1 |
| Planchon, SM | 4 |
| Wuerzberger, S | 1 |
| Frydman, B | 1 |
| Witiak, DT | 1 |
| Hutson, P | 1 |
| Church, DR | 1 |
| Wilding, G | 1 |
| Wuerzberger, SM | 1 |
| Byers, KL | 1 |
| Tagliarino, C | 3 |
| Varnes, ME | 1 |
| Siegel, D | 1 |
| Wuerzberger-Davis, S | 1 |
| Yang, X | 1 |
| Froelich, CJ | 1 |
| Dubyak, GR | 1 |
| Nieminen, AL | 1 |
18 other studies available for beta-lapachone and Breast Cancer
| Article | Year |
|---|---|
Mitochondrial activity is the key to the protective effect of β-Lapachone, a NAD
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cisplatin; Female; Humans; Mitochondria; | 2022 |
STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Electron Transpo | 2021 |
ConA-Coated Liposomes as a System to Delivery β-Lapachone to Breast Cancer Cells.
Topics: Breast Neoplasms; Concanavalin A; Female; Humans; Liposomes; Naphthoquinones | 2022 |
β-lapachone suppresses tumour progression by inhibiting epithelial-to-mesenchymal transition in NQO1-positive breast cancers.
Topics: Animals; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; D | 2017 |
Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Death; Cell Survival; | 2018 |
NQO1 is Required for β-Lapachone-Mediated Downregulation of Breast-Cancer Stem-Cell Activity.
Topics: Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Humans; Immunohistochemistry; | 2018 |
Protein kinase A activation by β‑Lapachone is associated with apoptotic cell death in NQO1‑overexpressing breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cyclic AMP-Dependent Protein Kinases; Enzyme Activati | 2019 |
Synergistic enhancement of antitumor effect of β-Lapachone by photodynamic induction of quinone oxidoreductase (NQO1).
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Light; MCF-7 Cells; NAD(P)H Deh | 2013 |
Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.
Topics: Breast Neoplasms; Catalase; DNA Breaks, Single-Stranded; DNA Damage; Female; Gene Expression Regulat | 2013 |
Inactivation of β-Lapachone Cytotoxicity by Filamentous Fungi that Mimic the Human Blood Metabolism.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line; Cell Line, Tumor; Female; Fibroblasts; Fungi; Hu | 2017 |
β-lapachone significantly increases the effect of ionizing radiation to cause mitochondrial apoptosis via JNK activation in cancer cells.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; bcl-2-A | 2011 |
Administration of the optimized β-Lapachone-poloxamer-cyclodextrin ternary system induces apoptosis, DNA damage and reduces tumor growth in a human breast adenocarcinoma xenograft mouse model.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cyclo | 2013 |
Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-kappaB-dependent XIAP up-regulation.
Topics: Active Transport, Cell Nucleus; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apop | 2004 |
Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response.
Topics: Apoptosis; Breast Neoplasms; Camptothecin; Cell Division; Dimethyl Sulfoxide; Drug Screening Assays, | 1995 |
Induction of apoptosis in MCF-7:WS8 breast cancer cells by beta-lapachone.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Cycle | 1998 |
NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity.
Topics: Antibiotics, Antineoplastic; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Division; Cytochro | 2000 |
Activation of a cysteine protease in MCF-7 and T47D breast cancer cells during beta-lapachone-mediated apoptosis.
Topics: Antibiotics, Antineoplastic; Apoptosis; Breast Neoplasms; Cysteine Endopeptidases; Enzyme Activation | 2000 |
Calcium is a key signaling molecule in beta-lapachone-mediated cell death.
Topics: 4-Nitroquinoline-1-oxide; Adenosine Triphosphate; Apoptosis; Blotting, Western; Breast Neoplasms; Ca | 2001 |